Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Venous Thromboembolism Prophylaxis in Orthopedic Surgery

Slide: 25 of 30

Summary of the RECORD Trials

After the comparative effectiveness review was completed, rivaroxaban, an oral factor Xa inhibitor, was approved by the U.S. Food and Drug Administration (FDA) for this population of patients based primarily on the four Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous Thrombosis and Pulmonary Embolism (RECORD) trials. Rivaroxaban decreased the risk of the composite primary outcome of DVT, nonfatal PE, or all-cause mortality in patients undergoing major orthopedic surgery.

Abbreviations: DVT = deep vein thrombosis; PE = pulmonary embolism; THR = total hip replacement; TKR = total knee replacement